During the first and second quarters of 2023, Sulfadiazine, a pharmaceutical class primarily employed for bacterial infection treatment, exhibited a market performance intricately linked to the overall performance of the pharmaceutical sector in India. This connection was reinforced by the government’s endeavors to bolster drug production and promote imports, with the goal of mending disrupted […]
